Insights On Trial Design

1. Why Inclusive Clinical Trials Win On Science, Speed, And Spend 9/17/2025

   Sponsors who proactively integrate diversity into their trial designs from the earliest phases are finding that it’s not only a matter of fairness but a strategic advantage.

2. Can Patient Liaison Services Transform Clinical Research Access? 9/25/2025

   Patients often face invisible hurdles in research. Watch how Patient Liaison services can change the journey for participants, sites, and sponsors, making trials easier to join and stay in.

3. Insights Into Chronic Lymphocytic Leukemia 8/28/2024

   In this FAQ, we delve into various aspects of Chronic Lymphocytic Leukemia (CLL), including its incidence and prevalence, the latest clinical trials, and the development of innovative drug therapies.

4. The Hidden Healthcare Benefits That Home Trial Support Provides 7/22/2025

   Examine how Home Trial Support (HTS) enhances both patient and caregiver safety and well-being, while alleviating pressures on sites and generating greater ROI for sponsors.

5. How To Improve Patient Outcomes Using eSource Software In Clinical Trials 8/11/2025

   As the demand for patient-centric clinical trials grows, eSource platforms will play an increasingly vital role in facilitating efficient, compliant, and innovative research methodologies.

6. Overview Of Diffuse Large B-cell Lymphoma: Global Clinical Trial Landscape 11/15/2024

   Diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma subtype, has varied molecular profiles, global incidence, innovative drugs, and trials improving treatment strategies and patient outcomes.

7. Why EHR Data Is The Game Changer For Life Sciences Success 5/26/2025

   The pharmaceutical industry faces soaring costs and shrinking ROI. Discover why leveraging rich real-world data is now essential for driving efficiency, innovation, and competitive advantage.

8. Cell And Gene Therapy Field Quiet In Q2 8/15/2024

   While there weren't any new gene or cell therapy approvals in Q2 2024, the U.S. approved two RNA therapies: Rytelo, an oligonucleotide telomerase inhibitor, and mRESVIA, an mRNA vaccine.

9. What Does 2025 Hold For Pharma? 1/17/2025

   Look at what’s in store for pharma and life science in 2025. While we see many recurring themes, 2025 promises to be filled with unexpected — and possibly unprecedented — developments.

10. Taking Research In-House With CRIO: SciTech's Multi-Center Phase 1 Study 1/6/2025

    Explore the success story of an early-stage clinical pharmaceutical company that effectively navigated funding constraints when conducting its Phase 1 study without a third-party CRO.